Mark W. Rixon
43Patents
8h-index
44Co-inventors
75Inventor score
Filing activity: Feb 16, 1993 → Aug 16, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5472693A | Family of anti-carcinoembryonic antigen chimeric antibodies | Chemistry; Metallurgy | 43 | Expired |
| US7501497B2 | TACI-immunoglobulin fusion proteins | Chemistry; Metallurgy | 20 | Expired |
| US7635767B2 | Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same | Chemistry; Metallurgy | 12 | Active |
| US7122632B2 | Soluble Interleukin-20 receptor | Chemistry; Metallurgy | 11 | Expired |
| US5993813A | Family of high affinity, modified antibodies for cancer treatment | Chemistry; Metallurgy | 10 | Expired |
| US7622116B2 | Method of treating inflammation using soluble IL-17RCX4 | Chemistry; Metallurgy | 9 | Active |
| US8945553B2 | Bispecific antibodies to IL-23 and IL-17A/F | Chemistry; Metallurgy | 8 | Active |
| US7842665B2 | IL-17A and IL-17F antagonists | Emerging Cross-Sectional Technologies | 8 | Active |
| US7951919B2 | TACI-immunoglobulin fusion proteins | Chemistry; Metallurgy | 5 | Active |
| US5808033A | Family of anti-carcinoembryonic antigen chimeric antibodies | Chemistry; Metallurgy | 5 | Expired |
| US7862814B2 | Method of inhibiting the proliferation of B cell cancers using TACI-immunoglobulin fusion proteins | Chemistry; Metallurgy | 5 | Active |
| US6207815A | Family of high affinity, modified antibodies for cancer treatment | Chemistry; Metallurgy | 4 | Expired |
| US7964711B2 | Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same | Chemistry; Metallurgy | 4 | Active |
| US7883700B2 | Anti-human IL-21 monoclonal antibodies | Emerging Cross-Sectional Technologies | 3 | Active |
| US9346878B2 | Methods of treating glomerulonephritis associated with IGA nephropathy for TACI-immunoglobulin fusion proteins | Chemistry; Metallurgy | 3 | Active |
| US8815238B2 | Methods for Preparing TACI-immunoglobulin fusion proteins | Chemistry; Metallurgy | 3 | Active |
| US8524232B2 | Methods of treatment using taci-immunoglobulin fusion proteins | Chemistry; Metallurgy | 3 | Active |
| US7790676B2 | Soluble IL-17RA/RC fusion proteins | Chemistry; Metallurgy | 2 | Active |
| US6329175A | Interferon-.epsilon. | Chemistry; Metallurgy | 2 | Expired |
| US8093355B2 | Soluble IL-17RCx4 and fusion proteins thereof | Chemistry; Metallurgy | 2 | Active |
| US8084231B2 | Soluble IL-17RA/RC fusion proteins and related methods | Chemistry; Metallurgy | 2 | Active |
| US11274140B2 | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US6051225A | Family of high affinity, modified antibodies for cancer treatment | Chemistry; Metallurgy | 2 | Expired |
| US8658766B2 | Soluble hybrid Fcγ receptors and related methods | Human Necessities | 2 | Active |
| US7387780B2 | Soluble interleukin-20 receptor | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.